-Deficiency in cortistatin could be further examined as a potential
biomarker of susceptibility or poor-prognosis of developing severe
hepatic fibrosis and cirrhosis.
-Cortistatin-based therapies could serve for treating chronic hepatic
disorders of different aetiologies to reduce disease severity and
mortality.